Prostate Cancer Survival Outcomes Influenced by Metastatic Sites
Understanding Prostate Cancer Prognosis
Prostate cancer is the fourth most diagnosed cancer in men and the eighth leading cause of cancer death worldwide. While localized prostate cancer often leads to favorable survival outcomes, metastatic prostate cancer (mPC) carries a significant risk of mortality. A recent retrospective analysis evaluated how various visceral metastatic sites influence prognosis in patients with prostate cancer.
Metastatic Sites and Survival Rates
In this study, involving 59,875 patients, 39,495 (65.2%) had bone metastases, while others were categorized into lung (12.5%), brain (8.7%), and liver (12.5%) only metastases:
- Median overall survival (OS) for all patients was 15.7 months.
- Bone metastases exhibited the longest median OS at 44.4 months.
- Lung metastases followed with a median OS of 31.9 months.
- Conversely, brain and liver metastases had significant declines in median OS, recorded at 9.6 months and 10 months, respectively.
Analysis of Multiple Metastatic Sites
Patients with dual metastatic sites faced concerning survival metrics:
- Liver and lung metastases presented a median OS of 8 months.
- Liver and lung simultaneous metastases dropped to a median OS of 6.6 months.
- However, liver and brain metastases were the direst, with a median OS of just 3.1 months.
Notably, patients with liver and brain metastases exhibited a significantly lower median OS compared to those with liver and lung metastases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.